Correspondence 0001493152-25-003745 from MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313) (MAIA)
MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313)
Date: Jan. 27, 2025 · CIK: 0001878313 · Accession: 0001493152-25-003745
AI Filing Summary & Sentiment
Reasoning
Referenced dates: January 22, 2025
Letter
VIA EDGAR United States Securities and Exchange Commission Attention: Nicholas Panos Re: MAIA Biotechnology, Inc. Schedule 13D Filed by Louie Ngar Yee Filed October 25, 2024
Dear Ladies and Gentlemen:
This letter sets forth responses on behalf of Louie Ngar Yee, reporting person (the “Reporting Person”), to the comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in its letter dated January 22, 2025 (the “Comment Letter”) regarding the Reporting Person’s Schedule 13D filed on October 25, 2024 (File No. 005-93731)
For the convenience of the Staff, each comment from the Comment Letter corresponds to the numbered paragraphs in this letter and is restated prior to the response to such comment.
Schedule 13D Filed October 25, 2024
General
1. We note that the event reported as requiring the filing of the Schedule 13D was March 14, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the March 14, 2024 event date, the Schedule 13D submitted on October 25, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date of the acquisition.
Response: The Schedule 13D was not filed within the required five business days after the date of the acquisition due to an oversight on the part of the Reporting Person. Following the March 14, 2024 event date (the “Event Date”), the Reporting Person timely disclosed its beneficial ownership of shares of MAIA Biotechnology Inc. (the “Company”) common stock on a Form 4. Upon the Reporting Person becoming aware of the oversight, they caused the Schedule 13D to be filed as promptly as possible. The failure to meet the deadline was not deliberate on the part of the Reporting Person, and the Reporting Person does not believe they gained any advantage as a result of the filing of the Schedule 13D past the deadline. The Reporting Person now understands the requirements and importance of compliance with Section 13(d) filing timelines and will work to ensure that future filings will be made in a timely manner.
* * *
-1-
Sheppard, Mullin, Richter & Hampton LLP
Rockefeller Plaza
New York, New York 10112-0015
212.653.8700 main
212.653.8701 fax
www.sheppardmullin.com
Should you have any questions regarding the foregoing, please do not hesitate to contact Richard Friedman at (212) 634-3031.
Sincerely,
Sheppard
Mullin Richter & Hampton LLP
Show Raw Text
CORRESP
1
filename1.htm
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, New York 10112-0015
212.653.8700
main
212.653.8701
fax
www.sheppardmullin.com
January
27, 2025
VIA
EDGAR
United
States Securities and Exchange Commission
100
F. Street, NE
Washington,
DC 20549
Attention:
Brian
Soares
Nicholas
Panos
Re:
MAIA Biotechnology, Inc.
Schedule 13D Filed by Louie Ngar Yee
Filed October 25, 2024
Dear
Ladies and Gentlemen:
This
letter sets forth responses on behalf of Louie Ngar Yee, reporting person (the “Reporting Person”), to the comments received
from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in its letter
dated January 22, 2025 (the “Comment Letter”) regarding the Reporting Person’s Schedule 13D filed on October 25, 2024
(File No. 005-93731)
For
the convenience of the Staff, each comment from the Comment Letter corresponds to the numbered paragraphs in this letter and is restated
prior to the response to such comment.
Schedule
13D Filed October 25, 2024
General
1.
We note that the event reported as requiring the filing of the Schedule 13D was March 14, 2024. Rule 13d-1(a) of Regulation 13D-G requires
the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity
securities specified in Rule 13d-1(i)(1) was acquired. Based on the March 14, 2024 event date, the Schedule 13D submitted on October
25, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date
of the acquisition.
Response:
The Schedule 13D was not filed within the required five business days after the date of the acquisition due to an oversight on the part
of the Reporting Person. Following the March 14, 2024 event date (the “Event Date”), the Reporting Person timely disclosed
its beneficial ownership of shares of MAIA Biotechnology Inc. (the “Company”) common stock on a Form 4. Upon the Reporting
Person becoming aware of the oversight, they caused the Schedule 13D to be filed as promptly as possible. The failure to meet the deadline
was not deliberate on the part of the Reporting Person, and the Reporting Person does not believe they gained any advantage as a result
of the filing of the Schedule 13D past the deadline. The Reporting Person now understands the requirements and importance of compliance
with Section 13(d) filing timelines and will work to ensure that future filings will be made in a timely manner.
*
* *
-1-
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, New York 10112-0015
212.653.8700
main
212.653.8701
fax
www.sheppardmullin.com
Should
you have any questions regarding the foregoing, please do not hesitate to contact Richard Friedman at (212) 634-3031.
Sincerely,
Sheppard
Mullin Richter & Hampton LLP
/s/ Sheppard Mullin Richter
& Hampton LLP
cc:
Louie Ngar Yee
-2-